Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 7Neoplasm Metastasis 2Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Colonic Neoplasms 1Carcinoma 1Adenocarcinoma 1

Interventions

Gemcitabine 42130-nm albumin-bound paclitaxel 26Albumin-Bound Paclitaxel 18Irinotecan 16Oxaliplatin 14Fluorouracil 14pembrolizumab 13Nivolumab 13Magnetic Resonance Spectroscopy 11Leucovorin 11Taxes 10Specimen Handling 9Biopsy 9Cisplatin 8Capecitabine 7folfirinox 6Radiotherapy 6Carboplatin 6irinotecan sucrosofate 5durvalumab 5Ipilimumab 5Cyclophosphamide 5olaparib 4defactinib 4Surveys and Questionnaires 4Standard of Care 4Radiosurgery 4Immunoglobulin G 4Disulfides 4dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Pancreatic Neoplasms × Trifluridine × Clear all
NCT03368963 2025-01-07

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Emory University

Phase 1/2 Active not recruiting
64 enrolled
Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡